Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M66.7Revenue $M0.1Net Margin (%)--Altman Z-Score0.1
Enterprise Value $M45.2EPS $-0.1Operating Margin %--Piotroski F-Score2
P/E(ttm)--Beneish M-Score-4.1Pre-tax Margin (%)--Higher ROA y-yY
Price/Book3.710-y EBITDA Growth Rate %-2.4Quick Ratio7.1Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %-2.4Current Ratio7.1Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-45.5Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-58.4Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M181ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with RNN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
RNNKen Fisher 2014-09-30 Sold Out $0.662 - $0.875
($0.75)
$ 0.37-51%Sold Out0
RNNKen Fisher 2014-06-30 Buy $0.79 - $1.28
($0.95)
$ 0.37-61%New holding10,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

RNN is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


RNN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Jeong Tae HeumCFO 2015-01-12Sell317,272$0.91-59.34view
Ahn Chang HoDirector 2015-01-12Sell314,656$0.91-59.34view
Ahn Chang HoDirector 2014-06-12Sell136,193$0.99-62.63view
Jeong Tae HeumCFO 2013-09-09Sell71,139$0.46-19.57view
Kivel RichardDirector 2011-10-03Buy2,500$1.04-64.42view
Brandt Peter C.Director 2011-09-09Buy125,000$1.17-68.38view
Brandt Peter C.Director 2011-09-07Buy25,000$0.96-61.46view
Ahn Chang HoChairman & CEO, 10% Owner 2011-05-18Buy1,008,078$1.31-71.76view
Ahn Chang HoChairman & CEO, 10% Owner 2011-04-01Buy320,846$1.22-69.67view
McIntosh David MDirector 2009-07-30Buy5,600$0.8-53.75view

Quarterly/Annual Reports about RNN:

    News about RNN:

    Articles On GuruFocus.com
    Weekly CEO Buys Highlight: RNN, IIG, FSC, GEO, DAN May 21 2011 
    Weekly CEO Buys Highlight: GBDC, EXL, RNN, KYN, CMTL Apr 09 2011 

    More From Other Websites
    Rexahn Pharmaceuticals Completes Stage 1 and Begins Enrollment in Stage 2 of Archexin® Phase IIa... Feb 08 2016
    Rexahn Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference on Monday,... Feb 01 2016
    Rexahn Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference on Monday,... Feb 01 2016
    Rexahn Pharmaceuticals Announces Supinoxin™ Poster Presentations at the 2016 Gastrointestinal... Jan 25 2016
    Rexahn Pharmaceuticals Announces Supinoxin™ Poster Presentations at the 2016 Gastrointestinal... Jan 25 2016
    BioWatch News' Alan Leong Interviewed by The Life Sciences Report Jan 22 2016
    New Preclinical Data for Supinoxin™ Show Oral Administration Produces Clinically Meaningful Tumor... Jan 12 2016
    New Preclinical Data for Supinoxin™ Show Oral Administration Produces Clinically Meaningful Tumor... Jan 12 2016
    Rexahn Pharmaceuticals' Archexin® Shows Dose-Dependent Tumor Reduction in a Phase IIa Clinical... Jan 11 2016
    Rexahn Pharmaceuticals’ Archexin® Shows Dose-Dependent Tumor Reduction in a Phase IIa Clinical... Jan 11 2016
    Rexahn Pharmaceuticals to Present at Biotech Showcase™ 2016 Jan 05 2016
    Rexahn Pharmaceuticals to Present at Biotech Showcase™ 2016 Jan 05 2016
    BioNap Consulting's Jason Napodano Interviewed by The Life Sciences Report Dec 18 2015
    Rexahn Pharmaceuticals Announces New Data for Supinoxin™ Showing Potent Tumor Growth Inhibition Dec 14 2015
    Rexahn Pharmaceuticals Announces New Data for Supinoxin™ Showing Potent Tumor Growth Inhibition Dec 14 2015
    REXAHN PHARMACEUTICALS, INC. Financials Dec 08 2015
    Biotechs Under 20 Dollars Poised to Breakout Nov 23 2015
    REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Nov 12 2015
    Rexahn Pharmaceuticals to Present at the Stifel 2015 Healthcare Conference on November 18, 2015 Nov 11 2015
    REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Nov 06 2015

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK